Table 1 Demographic and clinical characteristics of the transplant study groups
Variables | Frequencies |
|---|---|
N (%) | |
Recipient gender: | |
- males | 65 (73%) |
- females | 24 (27%) |
Recipient age (years, mean±SD) | 52.5±11.5 |
Donor age (years, mean±SD) | 50.9±15.9 |
Donor gender: | |
- males | 59 (66%) |
- females | 30 (34%) |
Donor type: | |
- brain-dead donors | 84 (94.3%) |
- living donors | 5 (5.7%) |
Time on RRT (months, mean±SD) | 54.3±35.0 |
RRT type: | |
- haemodialysis | 74 (83.1%) |
- peritoneal dialysis | 15 (16.9%) |
No of HLA mismatches (median and IQR) | 3MM (1-5) |
Class I PRA (%, mean±SD) | 4.4±11.1 |
Class II PRA (%, mean±SD) | 1.8±7.8 |
CIT (minutes, mean±SD) | 630±265 |
WIT (minutes, mean±SD) | 44±13 |
Induction: | |
- basiliximab | 82 (92%) |
- anti-thymocyte globulins (rATG) | 7 (8%) |
Calcineurin inhibitor: | |
- cyclosporine | 14 (16%) |
- tacrolimus | 75 (84%) |
Proliferation signal inhibitor: | |
- everolimus | 12 (13%) |
- mycophenolic acid | 77 (87%) |
CMV-positive donor/CMV-negative recipient | 11 (12.4%) |
Previous transplantation | 6 (6.7%) |
Delayed graft function | 32 (36%) |